CNS Therapy raises more than CHF 1 million in seed round

With CHF 1 million in funding secured from private investors and additional CHF 139,200 in non-dilutive financial support from canton Jura, CNS Therapy is poised to embark on the next phase of its journey: completing all regulatory steps for market entry. Their mission is clear—to bring forth a non-invasive, low risk therapy for chronic pain sufferers in Switzerland and beyond.

While many traditional treatments for chronic pain rely on medications and implants, CNS Therapy offers a non-invasive, drug-free therapeutic approach. At the Marburg University Pain Clinic, chronic pain patients currently receive CNS Therapy’s treatment which combines a new physiological approach - the patented Systolic Extinction Therapy (SET) based on very precise electrical stimulations on patients’ fingers gated to their cardiac cycle - and eLearning-based behavioural therapy. Notably, within just one year of treatment, 82% of female patients with fibromyalgia – a chronic condition causing widespread body pain - reported absence of pain.

CNS Therapy is the 2022 winner of the DayOne Tech accelerator program, a 12-month program for medtech ventures in the Jura. It is located in the Switzerland Innovation Park Basel Area – site Jura. More information and an interview with CNS Therapy’s founder Marc Mathys can be found here.


(SR)